Human papillomavirus vaccine: Recommendations, issues and controversies

Current Opinion in Pediatrics

Volumn 20, Issue 4, 2008, Pages 441-445

  Fisher, Randall ^a,b   Darrow, David H ^a   Tranter, Margene ^b   Williams, Judith V ^a,b,c  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Children's Specialty Group   (United States)

^c NONE   (United States)

Author keywords

Human papillomavirus vaccine; Vaccination implementation; Vaccination requirements

Indexed keywords

HEPATITIS B VACCINE; WART VIRUS VACCINE;

AGE DISTRIBUTION; ANUS CANCER; CHILD WELFARE; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEPATITIS B; HUMAN; INFECTION PREVENTION; LUNG TUMOR; PAPILLOMATOSIS; PENIS CANCER; PRIORITY JOURNAL; REVIEW; TUMOR RECURRENCE; UNITED STATES; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRUS INFECTION; WART VIRUS; ADOLESCENT; ADULT; ADVISORY COMMITTEE; ATTITUDE TO HEALTH; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE PLANNING; IMMUNIZATION; MALE; MASS IMMUNIZATION; SEXUALLY TRANSMITTED DISEASE; STANDARD; UTERINE CERVIX TUMOR; VIROLOGY;

ADOLESCENT; ADULT; ADVISORY COMMITTEES; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PLANNING GUIDELINES; HUMANS; IMMUNIZATION SCHEDULE; MALE; MASS IMMUNIZATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEXUALLY TRANSMITTED DISEASES, VIRAL; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 52449102124     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328305e298     Document Type: Review

References (34)

1. Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 2007; 107:S2-S5.
2. Bishai D, Kashima H, Shah K. The cost of juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2000; 126:935-939.
3. Derkay CS, Schraff S. Survey of ASPO membership regarding management of RRP distal spread and the use of adjuvant therapies. Arch Otolaryngol Head Neck Surg 2004; 130:1039-1042.
4. Markowitz LE, Dunne EF, Saraiya M, et al. Quadravalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007; 56:1 -23.
5. American Academy of Pediatrics, Committee on Infectious Diseases. Prevention of human papillomavirus infections: provisional recommendations for immunization of girls and women with quadravalent human papillomavirus vaccine. Pediatrics 2007; 120:666-668.
6. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11,16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118:2135-2145.
7. Partridge J, Hughes J, Feng Q, et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort university students. J Infect Dis 2007; 196:1128-1136.
8. Giuliano A. Human papillomavirus vaccination in males. Gynecol Oncol 2007; 107:S24-S26.
9. Pallecaros A, Vonau B. Human papilloma virus vaccine: more than a vaccine. Curr Opin Obstet Gynecol 2007; 10:541 -546.
10. Urman CO, Gottlieb AB. New viral vaccines for dermatologic disease. J Am Acad Dermatol 2008; 58:361-370.
11. European Commission approves Gardasil, Merck's cervical cancer vaccine. http://www.merck.com/newsroom/press-releases/product/2006-0922a. html. [Accessed 27 March 2008].
12. Insinga R, Dasbach E, Elbasha E, et al. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007; 10:128-139.
13. Ortega-Sanchez IR, Lee GM, Jacobs RJ, et al. Projected cost-effectiveness of new vaccines for adolescents in the United States. Pediatrics 2008; 121: S63-S78.
14. Stanley M. Prevention strategies against the human papillomavirus: the effectiveness of vaccination. Gynecol Oncol 2007; 107:S19-S23.
15. Elbasha EH, Dasbach EJ, Insigna RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13:28-41.
16. Chesson HW, Ekwueme DU, Saraiya M, et al. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008; 14:244-251.
17. Schwartz JL, Caplan AL, Faden RR, et al. Lessons from the failure of human papillomavirus vaccine state requirements. Clin Pharmacol Ther 2007; 82:760-763.
18. Gardasil information for healthcare professionals. http://merckvaccines. com/ gardasilProductPage-frmst.html. [Accessed 27 March 2008].
19. Cutts FT, Franceschi S, Goldie S, et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ 2007; 85:719-726.
20. Charo RA. Politics, parents, and prophylaxis: mandating HPV vaccination in the United States. N Engl J Med 2007; 356:1905-1908.
21. Zimet GD, Shew ML, Kahn JA. Appropriate use of cervical cancer vaccine. Annu Rev Med 2008; 59:223-236.
22. Gostin LO, DeAngelis CD. Mandatory HPV vaccination: public health vs. private wealth. JAMA 2007; 297:1921 -1923.
23. Pitts M, Clarke T. Human papillomavirus infections and risks of cervical cancer: what do women know? Health Educ Res 2002; 17:706-714.
24. Raine TR, Harper CC, Rocca CH, et al. Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs: a randomized controlled trial. JAMA 2005; 293:54-62.
25. Haber G, Malow RM, Zimet GD. The HPV vaccine mandate controversy. J Pediatr Adolesc Gynecol 2007; 20:325-331.
26. Villa LL, Costa RLR, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95:1 459-1466.
27. Marlow LAV, Waller J, Wardle J. Parental attitudes to prepubertal HPV vaccination. Vaccine 2007; 25:1945-1952.
28. Woodhall SC, Lehtinen M, Verho T, et al. Anticipated acceptance of HPV vaccination at the baseline of implementation: a survey of parental and adolescent knowledge and attitudes in Finland. J Adolesc Health 2007; 40:466-469.
29. Tissot AM, Zimet GD, Rosenthatl SL, et al. Effective strategies for HPV vaccine delivery: the views of pediatricians. J Adolesc Health 2007; 41: 119-125.
30. Dempsey AF, Gebremariam A, Koutsky LA, et al. Using risk factors to predict human papillomavirus infection: implications for targeted vaccination strategies in young adult women. Vaccine 2008; 26:1111- 1117.
31. National Conference of State Legislatures. HPV Vaccine Legislation 2007- 2008. http://www.ncsl.org/programs/health/HPVvaccine.htm. [Accessed 13 March 2008].
32. Foerster V, Murtagh J. Human papillomavirus (HPV) vaccines: a Canadian update. Issues Emerg Health Technol 2007; 109:1-8.
33. Adams M, Jasani B, Fiander A. Human papillomavirus (HPV) vaccination: challenges for public health and implications for screening. Vaccine 2007; 25:3007-3013.
34. Ault KA. Long-term efficacy of human papillomavirus vaccination. Gynecol Oncol 2007; 107:S27-S30.